408 related articles for article (PubMed ID: 19041125)
1. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
Obradovic M; Mrhar A; Kos M
Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
5. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
6. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
[TBL] [Abstract][Full Text] [Related]
8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
10. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of human papilloma virus vaccination in Iceland.
Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
[TBL] [Abstract][Full Text] [Related]
12. Mathematical models of cervical cancer prevention in the Asia Pacific region.
Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
[TBL] [Abstract][Full Text] [Related]
13. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands.
Bogaards JA; Coupé VM; Meijer CJ; Berkhof J
Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961
[TBL] [Abstract][Full Text] [Related]
14. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
Westra TA; Daemen T; Postma MJ; Wilschut JC
Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
17. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]